Once-daily REQUIP XL was generally well tolerated
*A 36-week, multicenter, double-blind, cross-over study of 161 patients with early Parkinson's disease that compared REQUIP XL with immediate-release ropinirole.
- Patients receiving REQUIP XL achieved higher doses faster than those receiving immediate-release ropinirole during the titration process 2
As monotherapy, once-daily REQUIP XL demonstrated withdrawal rates due to adverse events comparable to immediate-release ropinirole
As adjunctive therapy, once-daily REQUIP XL demonstrated withdrawal rates due to adverse reactions comparable to placebo
NEXT:
Switching and Dosing for REQUIP XL
Important Safety Information
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.
Complete Prescribing Information for REQUIP XL
REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.
Complete Prescribing Information for REQUIP XL